Last 12 months
Inside the activity.
0 purchase rows · 10 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2020 Filed May 14, 2020 20:25 UTC |
Hutson Nancy JDirector
|
GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001127602-20-016569 · form4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-05-12 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:14 UTC |
ABERCROMBIE GEORGE BDirector
|
GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001127602-20-016548 · form4.xml · derivative · entry 1 ABERCROMBIE GEORGE B · CIK 0001485939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-05-12 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:18 UTC |
ASELAGE STEVEDirector
|
GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001127602-20-016559 · form4.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-05-12 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| April 30, 2020 Filed May 4, 2020 20:08 UTC |
Doyle AnthonyChief Financial Officer
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001127602-20-015179 · form4.xml · derivative · entry 1 Doyle Anthony · CIK 0001808688 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2020-04-30 F1 · shares: Initial Employee Option Grant, 200,000 of which become exercisable on the first anniversary of the grant date or upon termination if, within the first year of his employment, Mr. Doyle is impacted by a reduction in force at the Company, and the remainder of which will vest in three equal installments on the second, third and fourth anniversaries of the grant date. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 21:50 UTC |
Hutson Nancy JDirector
|
GrantCommon Stock | 3,333 | $3.00 | $9,999.00 |
DisclosureSEC source: 0001127602-20-009065 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,887 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000 Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 21:59 UTC |
ASELAGE STEVEDirector
|
GrantCommon Stock | 1,666 | $3.00 | $4,998.00 |
DisclosureSEC source: 0001127602-20-009094 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,092 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 21:56 UTC |
HEGGIE THERESADirector
|
GrantCommon Stock | 1,666 | $3.00 | $4,998.00 |
DisclosureSEC source: 0001127602-20-009089 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,092 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 21:47 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 6,250 | $3.00 | $18,750.00 |
DisclosureSEC source: 0001127602-20-009058 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,916 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 22:09 UTC |
LEVIN ALAN GDirector
|
GrantNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001127602-20-009112 · form4.xml · derivative · entry 1 LEVIN ALAN G · CIK 0001174452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-02-27 F1 · shares: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:49 UTC |
Jones Michael LExec. Director, Finance - PAO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 2,800 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-007687 · form4.xml · derivative · entry 1 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Underlying: Common Stock · 2,800 shares Expires 2024-12-22 F1 · date: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:44 UTC |
Barnes Alane PSenior VP, Chief Legal Officer
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 12,400 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-007677 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,400 Underlying: Common Stock · 12,400 shares Expires 2024-12-22 F1 · date: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:42 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-007672 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2024-12-22 F1 · date: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:31 UTC |
Sheridan William PSenior VP - CMO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 22,600 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-007640 · form4.xml · derivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,600 Underlying: Common Stock · 22,600 shares Expires 2024-12-22 F1 · date: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:28 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-007625 · form4.xml · derivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2024-12-22 F1 · date: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:25 UTC |
Stonehouse Jon PDirector · President & CEO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 27,140 | $0.00 Strike: $12.16 | $0.00 |
DisclosureSEC source: 0001127602-20-007615 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,140 Underlying: Common Stock · 27,140 shares Expires 2025-01-01 F1 · date: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to Mr. Stonehouse in January 2015 has been met. Therefore, 20% of the performance-based stock options vested. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 22:13 UTC |
Jones Michael LExec. Director, Finance - PAO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 4,900 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-006508 · form4.xml · derivative · entry 1 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 Underlying: Common Stock · 4,900 shares Expires 2024-12-22 F1 · date: On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 22:03 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 31,500 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-006501 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2024-12-22 F1 · date: On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 22:11 UTC |
Barnes Alane PSenior VP, Chief Legal Officer
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 21,700 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-006505 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,700 Underlying: Common Stock · 21,700 shares Expires 2024-12-22 F1 · date: On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 22:00 UTC |
Sheridan William PSenior VP - CMO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 39,550 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-006497 · form4.xml · derivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,550 Underlying: Common Stock · 39,550 shares Expires 2024-12-22 F1 · date: On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:57 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 31,500 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-006488 · form4.xml · derivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2024-12-22 F1 · date: On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:53 UTC |
Stonehouse Jon PDirector · President & CEO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 47,495 | $0.00 Strike: $12.16 | $0.00 |
DisclosureSEC source: 0001127602-20-006477 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,495 Underlying: Common Stock · 47,495 shares Expires 2025-01-01 F1 · date: On February 18, 2019, the company announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to Mr. Stonehouse in January 2015 has been met. Therefore, 35% of the performance-based stock options vested. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:49 UTC |
Sniecinski MeganChief Business Officer
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 202,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035549 · form4.xml · derivative · entry 1 Sniecinski Megan · CIK 0001781480 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,000 Underlying: Common Stock · 202,000 shares Expires 2029-12-17 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:52 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035551 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2029-12-17 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:55 UTC |
Barnes Alane PSenior VP, Chief Legal Officer
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035553 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2029-12-17 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:36 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035544 · form4.xml · derivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2029-12-17 F1 · shares: Annual Employee option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:47 UTC |
Sheridan William PSenior VP - CMO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 176,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035547 · form4.xml · derivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,000 Underlying: Common Stock · 176,000 shares Expires 2029-12-17 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:34 UTC |
Stonehouse Jon PDirector · President & CEO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 314,500 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035542 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,500 Underlying: Common Stock · 314,500 shares Expires 2029-12-17 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 17, 2019 Filed Dec 26, 2019 22:09 UTC Amendment |
STAAB THOMAS R IISenior Vice President and CFO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 127,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035849 · form4a.xml · derivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,000 Underlying: Common Stock · 127,000 shares Expires 2029-12-17 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 17, 2019 Filed Dec 26, 2019 22:13 UTC Amendment |
Sniecinski MeganChief Business Officer
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035852 · form4a.xml · derivative · entry 1 Sniecinski Megan · CIK 0001781480 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2029-12-17 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:14 UTC |
ASELAGE STEVEDirector
|
GrantCommon Stock | 1,754 | $2.85 | $4,998.90 |
DisclosureSEC source: 0001127602-19-034168 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,426 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:17 UTC |
HEGGIE THERESADirector
|
GrantCommon Stock | 1,754 | $2.85 | $4,998.90 |
DisclosureSEC source: 0001127602-19-034170 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,426 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:12 UTC |
Hutson Nancy JDirector
|
GrantCommon Stock | 3,508 | $2.85 | $9,997.80 |
DisclosureSEC source: 0001127602-19-034165 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,554 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:09 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 6,578 | $2.85 | $18,747.30 |
DisclosureSEC source: 0001127602-19-034162 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,666 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:14 UTC |
LEE KENNETH B JRDirector
|
PurchaseCommon Stock | 5,000 | $1.45 | $7,250.00 |
DisclosureSEC source: 0001127602-19-033029 · form4.xml · nonDerivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,252 Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:16 UTC |
Sniecinski MeganChief Business Officer
|
PurchaseCommon Stock | 45,000 | $1.45 | $65,250.00 |
DisclosureSEC source: 0001127602-19-033033 · form4.xml · nonDerivative · entry 1 Sniecinski Megan · CIK 0001781480 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:17 UTC |
Stonehouse Jon PDirector · President & CEO
|
PurchaseCommon Stock | 50,000 | $1.45 | $72,500.00 |
DisclosureSEC source: 0001127602-19-033035 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 778,086 Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:12 UTC |
INGRAM ROBERT ALEXANDERDirector
|
PurchaseCommon Stock | 20,000 | $1.45 | $29,000.00 |
DisclosureSEC source: 0001127602-19-033025 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,088 Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:10 UTC |
Hutson Nancy JDirector
|
PurchaseCommon Stock | 10,000 | $1.45 | $14,500.00 |
DisclosureSEC source: 0001127602-19-033022 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,046 Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:08 UTC |
HEGGIE THERESADirector
|
PurchaseCommon Stock | 5,000 | $1.45 | $7,250.00 |
DisclosureSEC source: 0001127602-19-033017 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,672 Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:05 UTC |
Barnes Alane PSenior VP, Chief Legal Officer
|
PurchaseCommon Stock | 20,000 | $1.45 | $29,000.00 |
DisclosureSEC source: 0001127602-19-033008 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,061 Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:01 UTC |
ASELAGE STEVEDirector
|
PurchaseCommon Stock | 15,000 | $1.45 | $21,750.00 |
DisclosureSEC source: 0001127602-19-033001 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,672 Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:03 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
PurchaseCommon Stock | 25,000 | $1.45 | $36,250.00 |
DisclosureSEC source: 0001127602-19-033004 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,587 Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 20:27 UTC |
Thackray Helen M.Director
|
GrantNon-Qualified Stock Option · Derivative | 40,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001127602-19-029012 · form4.xml · derivative · entry 1 Thackray Helen M. · CIK 0001589725 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-09-20 F1 · shares: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan. Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 20:16 UTC |
HEGGIE THERESADirector
|
GrantCommon Stock | 1,672 | $2.99 | $4,999.28 |
DisclosureSEC source: 0001127602-19-027871 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,672 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 20:14 UTC |
ASELAGE STEVEDirector
|
GrantCommon Stock | 1,672 | $2.99 | $4,999.28 |
DisclosureSEC source: 0001127602-19-027867 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,672 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 20:12 UTC |
Hutson Nancy JDirector
|
GrantCommon Stock | 3,344 | $2.99 | $9,998.56 |
DisclosureSEC source: 0001127602-19-027862 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,046 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 20:08 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 6,270 | $2.99 | $18,747.30 |
DisclosureSEC source: 0001127602-19-027858 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,088 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:25 UTC |
Sniecinski MeganChief Business Officer
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-19-023901 · form4.xml · derivative · entry 1 Sniecinski Megan · CIK 0001781480 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-07-01 F1 · shares: Inducement option grant becomes exercisable at the rate of 30% on the first anniversary of the grant date with the remainder vesting in three equal installments on the second, third and fourth anniversaries of the grant date. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:13 UTC |
ASELAGE STEVEDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001127602-19-020302 · form4.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-29 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:23 UTC |
LEE KENNETH B JRDirector
|
GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001127602-19-020314 · form4.xml · derivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-29 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.